OS
OSRH.US OSR Holdings Inc
- Market cap
- USD 4.11M
- P/E
- -
- P/B
- 0.04x
- ROE
- -7.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OSRH.US undervalued?
Graham numberThe Graham number of OSR Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OSR Holdings Inc fundamental analysis
No fundamental analysis for OSR Holdings Inc yet.
OSR Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OSR Holdings Inc
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1…
Full company profileOSR Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OSR Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 0.00 | 3.53M | 2.91M | 1.60M |
| Gross Profit | - | - | 0.00 | 921K | 811K | 593K | -4.36M |
| Operating Income | -23.8K | -3.31K | -35.4K | -1.83M | -11.7M | -18.3M | -13.4M |
| EBITDA | -23.8K | 233K | -35.4K | 2.78M | -2.15M | -19.1M | -1.06M |
| Net Income | -23.8K | -3.31K | -35.4K | 404K | -10.3M | -18.0M | -7.87M |
| EPS | 0.00 | 0.00 | 0.00 | 0.05 | -2.30 | -4.02 | -1.76 |
| Balance Sheet | |||||||
| Total Assets | 323K | 705K | 96.0K | 36.6M | 2.30M | 171M | 167M |
| Total Liabilities | 322K | 707K | 17.2K | 40.5M | 8.79M | 44.2M | 41.7M |
| Shareholders' Equity | 1.19K | -2.12K | 78.8K | -3.91M | -6.49M | 77.6M | 104M |
| Cash & Short-term Investments | 62.7K | 4.76K | 2.24K | 15.4K | 66.1K | 1.70M | 1.50M |
| Total Debt | 300K | 400K | 1.24K | 72.0K | 2.64M | 4.40M | 578K |
| Cash Flow | |||||||
| Operating Cash Flow | -23.8K | -461.00 | -410.00 | -819K | -2.19M | -4.33M | -6.84M |
| Capital Expenditure | 2.00 | 1.00 | 61.52 | 4.00 | 4.00 | 176K | 16.00 |
| Free Cash Flow | -23.8K | -461.00 | -471.90 | -819K | -2.19M | -4.50M | -6.84M |
| Ratios | |||||||
| ROE | -2,004.4% | - | -44.9% | - | - | -23.2% | -7.5% |
| ROA | -7.4% | -0.5% | -36.9% | 1.1% | -448.5% | -10.5% | -4.7% |
| Net Profit Margin | - | - | - | - | -292.6% | -619.8% | -492.1% |
| Debt to Equity | 252.53x | - | 0.02x | - | - | 0.06x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OSR Holdings Inc dividends
OSR Holdings Inc has not paid dividends in the last 6 fiscal years.
Who owns OSR Holdings Inc
- Insiders 44.70%
- Institutions 0.19%
- Public & others 55.11%
- Shares outstanding 35.1M
- Free float 13.2M
Top funds holding OSRH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 89.3K | 0.25% | 0.00% | Jul 2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 37.4K | 0.11% | 0.00% | Jul 2026 |
| NT Ext Equity Mkt Index Fund - NL | 10.9K | 0.03% | 0.00% | Jun 2026 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 7.91K | 0.02% | 0.00% | Jun 2026 |
| Fidelity Series Total Market Index | 6.77K | 0.02% | 0.00% | Jul 2026 |
| Spartan Total Market Index Pool A1 | 4.35K | 0.01% | 0.00% | Jul 2026 |
| GAMCO Intl SICAV Merger Arbtrg I (USD) | 2.67K | 0.01% | -1.15% | Mar 2026 |
Top institutions holding OSRH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 128K | 0.36% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 106K | 0.30% | +84.53% | Mar 2026 |
| XTX Topco Ltd | 60.7K | 0.17% | 0.00% | Mar 2026 |
| The Toronto-Dominion Bank | 40.0K | 0.11% | 0.00% | Mar 2026 |
| Vanguard Capital Management, LLC | 37.4K | 0.11% | 0.00% | Mar 2026 |
| Vanguard Fiduciary Trust Co | 17.0K | 0.05% | 0.00% | Mar 2026 |
| StoneX Group Inc | 15.4K | 0.04% | 0.00% | Mar 2026 |
| Mint Tower Capital Management B.V. | 7.50K | 0.02% | 0.00% | Mar 2026 |
| UBS Group AG | 4.48K | 0.01% | -60.39% | Mar 2026 |
| Tower Research Capital LLC | 4.14K | 0.01% | -0.22% | Mar 2026 |
| Citigroup Inc | 384.00 | 0.00% | +7.26% | Mar 2026 |
| SBI Securities Co Ltd | 77.00 | 0.00% | +381.25% | Mar 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Point72 Asset Management, L.P. | 0.00 | 0.00% | -100.00% | Mar 2026 |
OSR Holdings Inc company profile
- Company name
- OSR Holdings Inc
- Ticker
- OSRH.US
- Exchange
- USA Stocks
- Listed since
- Mar 17, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- 10900 NE 4th Street, Bellevue, WA, United States, 98004
- Phone
- 425 635 7700
- Website
- osr-holdings.com
About OSR Holdings Inc
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
OSR Holdings Inc management
6- Mr. Kuk Hyoun HwangChairman & CEO · born 1976
- Mr. Gihyoun BangChief Financial Officer · born 1978
- Mr. Jun Chul WhangChief Legal Officer, Secretary & Director · born 1965
- Jessi KimChief Operating Officer
- Mr. Chankyu ParkChief Executive Officer of RMC · born 1975
- Mr. Tim SmithCorporate Secretary & Global IR